NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
12 Mar 2013

TiGenix to obtain national reimbursement in Spain for its innovative cartilage therapy ChondroCelect®

Leuven (BELGIUM), Madrid (SPAIN) – March 12, 2013 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative cartilage repair therapy ChondroCelect® will obtain national reimbursement in Spain.
12 Mar 2013

TiGenix Reports Full Year 2012 Financial Results

Leuven (BELGIUM) – March 12, 2013 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, today gave a business update and announced financial results for the full year 2012.
05 Mar 2013

Endosense closes an additional USD 4.3 million/CHF 4 million in series C financing

GENEVA – March 5, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, announced today that it has secured an additional USD 4.3 million/CHF 4 million in series C financing from a new strategic industry partner.
01 Feb 2013

First u.s. case performed with endosense’s tacticath quartz contact-force sensing ablation catheter

GENEVA – February 1, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its new generation TactiCath Quartz contact-force sensing ablation catheter has been used for the first time in the United States by Dr. J. Michael Mangrum at University of Virginia Medical Center in Charlottesville, Va.
Inbiomotion appoints Dr. David L. Lacey to its Board of Directors<
29 Jan 2013

Inbiomotion appoints Dr. David L. Lacey to its Board of Directors

Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience.
29 Jan 2013

TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid

Leuven (BELGIUM), Madrid (SPAIN) – January 29, 2013 – TiGenix (Euronext Brussels:TIG), a leader in the field of cell therapy, announced today that further to the cGMPinspection by the Spanish health authorities it has successfully renewed its manufacturingauthorization for stem cell products at its manufacturing facility in Madrid, Spain.
20 Dec 2012

TiGenix Completes Private Placement Raising EUR 6.7 million

Leuven, Belgium – 20 December 2012 – TiGenix NV (Euronext Brussels: TIG) announces today that it has raised EUR 6.7 million through a private placement via the accelerated bookbuilding procedure announced on 19 December 2012 after the market closed.
19 Dec 2012

TiGenix reports positive interim safety results of its Phase IIa study of Cx611

Leuven (BELGIUM), Madrid (SPAIN) – December 19, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA).
19 Dec 2012

TiGenix to Raise Capital via a Private Placement of New Ordinary Shares

Leuven, Belgium – 19 December 2012 – TiGenix NV (Euronext Brussels: TIG) today announced that it will launch a private placement of up to 8,629,385 new ordinary shares.
06 Dec 2012

Endosense appoints Nicolas Marsault as new CFO

GENEVA – December 6, 2012 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has named Nicolas Marsault as its new chief financial officer.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка